GlassScriptPhysician profile
Jana Lynn Chavous
NPI 1942729546
$4,201.97
in general payments reported to CMS, 2019-2025
37 companies · $1,553 in 2025
The $1,553 reported for 2025 was more than what 92% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $465 · 2022: $795 · 2023: $678 · 2024: $709 · 2025: $1,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558 · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.31 |
| Education | $382.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $632.94 | 2021-2025 | Calquence, Tagrisso, Lynparza |
| Astellas Pharma US INC | $322.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $318.89 | 2021-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $314.65 | 2022-2025 | Iclusig, Ninlaro, Advate |
| Novartis Pharmaceuticals Corporation | $300.99 | 2022-2025 | |
| Janssen Biotech, INC. | $291.44 | 2021-2025 | Carvykti, Rybrevant, Erleada |
| Lilly USA, LLC | $273.07 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $207.62 | 2024-2025 | |
| Incyte Corporation | $179.94 | 2022-2023 | |
| Seagen INC. | $153.73 | 2021-2023 | Padcev |
| Pfizer INC. | $128.84 | 2022-2025 | |
| Amgen INC. | $120.62 | 2021 | |
| Daiichi Sankyo INC. | $104.93 | 2023-2024 | Enhertu, Injectafer |
| Genzyme Corporation | $93.36 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $86.16 | 2022-2025 | Lynozyfic, Libtayo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $69.28 | 2024-2025 | |
| Eisai INC. | $61.83 | 2024-2025 | |
| Genentech USA, INC. | $58.95 | 2023-2025 | Phesgo, Polivy, Tecentriq |
| Genmab U.S., INC. | $53.94 | 2024-2025 | Epkinly |
| Celgene Corporation | $41.52 | 2021 | |
| Merck Sharp & Dohme LLC | $38.82 | 2023 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $37.17 | 2021-2025 | Opdivo |
| Geron Corporation | $33.43 | 2024-2025 | Rytelo |
| Adc Therapeutics America, INC. | $28.50 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.80 | 2024 | |
| Heron Therapeutics, INC. | $23.66 | 2022 | |
| Pharmaessentia USA Corporation | $22.86 | 2023 | Besremi |
| Alexion Pharmaceuticals, INC. | $21.23 | 2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $19.88 | 2025 | |
| Progenics Pharmaceuticals, INC. | $19.43 | 2024 | |
| Agios Pharmaceuticals, INC. | $19.37 | 2024 | Pyrukynd |
| Novo Nordisk INC | $18.97 | 2025 | Alhemo |
| Ipsen Biopharmaceuticals, INC | $17.05 | 2022 | |
| Stemline Therapeutics INC. | $15.76 | 2025 | Orserdu |
| Sobi, INC | $15.49 | 2025 | |
| Morphosys, US INC. | $15.10 | 2023 | Monjuvi |
| Kyowa Kirin, INC. | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jana Chavous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.